Harvard Innovation Labs Ventures in Biotech and Therapeutics

(This round-up is for informational purposes only and in alphabetical order.)

1) AbscoTx: Led by Stephen Linderman and the team, AbscoTx injects image-guided therapy into tumors to educate the immune system to fight cancer locally and at metastatic sites. Know More At: abscotx.com

2) Alvus Health Inc: Led by Junhan Zhao and the team, Alvus Health enables patient-derived epithelial organoids for high-throughput, multi-modal genetics-proteomics-histology phenotypic profiling, revolutionizing biopharma and medicare with AI. Know More At: alvushealth.com

3) Breaking: Led by co-founders Sukanya Punthambaker, PH.D, Vaskar Gnyawali, Ph.D, George Church, Ph.D, Donald Ingber, M.D., Ph.D, Alba Tull, Kent Wakeford, and Ben Lamm, Breaking is focused on engineering non-model organisms for unconventional applications. Know More At: breaking.com

4) Bullseye Biosciences: Led by Corey Gray and Michael McKeown, Bullseye Bio aims to transform therapeutics discovery and expedite the development of life-saving medicines. Know More At: bullseyebiosciences.com

5) CartaBio Inc: Led by co-founders Rob Yang, Ph.D, MBA, Ralph Weissleder, M.D., Ph.D., Hongzhi Wen, Ph.D., Yuying Xie, Ph.D, Jiliang Tang, Ph.D., and Mark Novas, M.D, MBA, CartaBio Inc is modulating cellular intelligence to redefine medicine. Know More At: cartabio.ai

6) Concerto Biosciences: Led by Cheri Ackerman, PhD, Jared Kehe, PhD, Bernardo Cervantes, PhD, and the team, Concerto Biosciences measures, maps, and harnesses the microbial world to create best-in-class therapies and products. Know More At: concertobio.com

7) Ephius Tx: Led by co-founders Amav Khambete, Dr. Mark Henkemeyer, Dr. Hanghang Wang, and Dr. Patrice Mimche, Ephius Tx is innovating targeted therapies to inhibit Eph-Ephrin over-expression for the treatment of fibrotic diseases, chronic inflammation, pain, obesity, and cancer. Know More At: ephiustx.com

8) GC Therapeutics: Led by co-founders Parastoo Khoshakhlagh, Alex Ng, George Church, Ph.D, and the team, GC Therapeutics is harnessing the world’s first “plug-and-play” induced pluripotent stem cell (iPSC) cellular programming platform, TFome™ (Transcription-Factor-ome, pronounced as tee-eff-ome), to overcome the development and scaling complexities associated with cell therapy and improve patient access across a broad range of therapeutic areas. Know More At: gc-tx.com

9) HarborSite: HarborSite is developing a next-generation gene insertion platform for the treatment of genetic and age-associated diseases. Know More At: harborsite.com